Results 51 to 60 of about 67,411 (205)

Hypokalemia secondary to capecitabine: a hidden toxicity?

Therapeutics and Clinical Risk Management, 2007
Background Hyopkalemia is a listed toxicity in the capecitabine (Xeloda®; Roche, Nutley, NJ) package insert. However, the incidence and severity of this toxicity is not known. Methods We performed a retrospective evaluation of hypokalemia in 77 patients,
Muhammad Wasif Saif, M. Fekrazad, L. Ledbetter, R. Diasio   +3 more
semanticscholar   +1 more source

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.
Xi Wang, Shusen Wang, Heng Huang, L. Cai, Li Zhao, Roujun Peng, Ying Lin, Jun Tang, J. Zeng, Lehong Zhang, Y. Ke, Xianming Wang, Xin-Mei Liu, Qianjun Chen, Anqin Zhang, Fei Xu, X. Bi, Jiajia Huang, Jibin Li, D. Pang, C. Xue, Yan-Xia Shi, Zhen-Yu He, Huan-xin Lin, X. An, W. Xia, Ye Cao, Ying Guo, Yanhong Su, X. Hua, Xinyue Wang, R. Hong, K. Jiang, Chenge Song, Zhangzan Huang, W. Shi, Y. Zhong, Zhongyu Yuan   +37 more
semanticscholar   +1 more source

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Clinical Cancer Research, 2022
Purpose: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and ...
Karama Asleh, A. Lluch, A. Goytain, C. Barrios, Xue Wang, L. Torrecillas, D. Gao, M. Ruíz-Borrego, S. Leung, J. Bines, A. Guerrero-Zotano, J. García-Saenz, J. Cejalvo, J. Herranz, R. Torres, J. R. De La Haba-Rodríguez, F. Ayala, H. Gómez, F. Rojo, T. Nielsen, Miguel Martín   +20 more
semanticscholar   +1 more source

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The Lancet Oncology, 2017
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
V. Diéras, D. Miles, S. Verma, M. Pegram, M. Welslau, J. Baselga, I. Krop, K. Blackwell, S. Hoersch, Jin Xu, M. Green, L. Gianni   +11 more
semanticscholar   +1 more source

Proton pump inhibitors affect capecitabine efficacy in patients with stage II–III colorectal cancer: a multicenter retrospective study

Scientific Reports, 2022
The association between capecitabine efficacy and proton pump inhibitors (PPIs) is controversial. Here, we determined whether co-administration of PPIs affects the real-world effectiveness of capecitabine.
Yoshiko Kitazume, H. Kawazoe, R. Uozumi, Tomoe Yoshizawa, H. Iihara, H. Fujii, Masaya Takahashi, T. Arai, Y. Murachi, Yumiko Sato, T. Mikami, Koji Hashiguchi, T. Yamazaki, Katsuyuki Takahashi, Yukiyoshi Fujita, Yuki Hosokawa, I. Morozumi, Masami Tsuchiya, Atsushi Yokoyama, H. Hashimoto, M. Yamaguchi   +20 more
semanticscholar   +1 more source

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

CPT: Pharmacometrics & Systems Pharmacology, 2019
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐fluorouridine (dFUR), 5 ...
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema   +9 more
doaj   +1 more source

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.

Annals of Oncology, 2020
BACKGROUND Palbociclib plus endocrine therapy (ET) is the standard treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC).
M. Martín, C. Zielinski, M. Ruíz-Borrego, E. Carrasco, N. Turner, E. Ciruelos, M. Muñoz, B. Bermejo, M. Margelí, A. Antón, Z. Kahán, T. Csöszi, M. Casas, L. Murillo, S. Morales, E. Alba, E. Gal-Yam, A. Guerrero-Zotano, L. Calvo, J. Haba-Rodríguez, M. Ramos, I. Álvarez, A. García-palomo, C. H. Bartlett, M. Koehler, R. Caballero, M. Corsaro, X. Huang, J. García-Saenz, J. Chacón, C. Swift, C. Thallinger, M. Gil-Gil   +32 more
semanticscholar   +1 more source

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

The Oncologist, 2021
Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine
S. Hurvitz, C. Saura, Mafalda Oliveira, M. Trudeau, B. Moy, S. Delaloge, W. Gradishar, Sung-Bae Kim, B. Haley, L. Ryvo, M. Dai, V. Milovanov, J. Alarcón, Sujith R. Kalmadi, E. Cronemberger, C. Souza, L. Landeiro, R. Bose, J. Bebchuk, F. Kabbinavar, R. Bryce, K. Keyvanjah, A. Brufsky   +22 more
semanticscholar   +1 more source

Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome

BMC Cancer
Background Hand-foot syndrome (HFS) is a common adverse event of capecitabine causing treatment modifications. Topical urea cream can reduce sorafenib-induced hand-foot skin reaction. However, its benefit in preventing capecitabine-associated HFS was not
Concord Wongkraisri, Kriengkrai Chusuwanrak, Apirom Laocharoenkeat, Leena Chularojanamontri, Akarin Nimmannit, Suthinee Ithimakin   +5 more
doaj   +1 more source

Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer

Case Reports in Oncology, 2021
Capecitabine is an oral chemotherapy that is used to treat several cancer types, including breast, gastrointestinal, hepatobiliary, and ovarian. The use of antimetabolites in cancer therapy has generally not been associated with leukemogenesis.
Sureerat Jaruhathai, Uraree Phornvoranunt, Waran Wannasirikul   +2 more
doaj   +1 more source